Simaravibart (MAD-0004J08) is a human IgG1κ monoclonal antibody designed to bind the SARS-CoV-2 spike protein's receptor-binding domain. It is a research tool for in vitro neutralization assays and in vivo studies investigating COVID-19 therapeutics and viral pathogenesis.